Phase 3 N=219 Subject Preference for Scalp Psoriasis Treatment
Scalp Psoriasis
Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=618 Treatment of Erectile Dysfunction I
Erectile Dysfunction
Primary: Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF…
Phase 3 N=601 Treatment of Erectile Dysfunction II
Erectile Dysfunction
Primary: Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF…
Phase 3 N=369 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy
Sarcoma, Soft Tissue
Primary: Progression-free Survival (PFS) — 7.0; 20.0 weeks — p=<0.001
Phase 3 N=65 A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
Epilepsies, Partial
Primary: Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) — 58; 13; 2; 0 Participants
Phase 3 N=80 Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain
Thyroid Carcinoma · Thyroidectomy
Primary: Postoperative Drainage Amount — 93.5; 105.7 mL
Phase 3 N=160 Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12 — 7.92; 7.97; -0.56; -0.22 Percentage of glycosylated hemoglobins — p=0.0063
Phase 3 N=410 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
Advanced Neuroendocrine Tumors of Pancreatic Origin
Primary: Time to Progression Free Survival (PFS) Based as Per Investigator Using Kaplan-Meier Methodology — 11.04; 4.60 Months
Phase 3 N=1,271 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
Hypoactive Sexual Desire Disorder
Primary: Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1…
Phase 3 N=903 Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Carcinoma, Renal Cell
Primary: Final Overall Survival (OS) - Primary Analysis in the ITT (Intent To Treat) Population — 542; 461 days — p=0.146
Phase 3 N=455 Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF]) — -0.73; -0.32 Percentage of change — p=<0.0001
Phase 3 N=239 Duloxetine for Multiple Sclerosis Pain
Multiple Sclerosis
Primary: Change From Baseline in the Weekly 24-Hour Average Pain Scores at Week 6 (Acute Phase) — -1.83; -1.07 units on a scale — p=0.001
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
Phase 3 N=220 A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
Neuralgia · Spinal Cord Injuries
Primary: Duration Adjusted Average Change (DAAC) of Mean Pain Score — -1.66; -1.07 score on scale — p=0.0032
Phase 3 N=60 Safety and Efficacy Study of a Eye Drop for Eye Allergy
Allergic Conjunctivitis
Primary: Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation. — 0.69; 2.27 units on a scale